Accelerating
Breakthroughs
In Detection and Diagnostics
Our aptamer platform accelerates breakthrough diagnostics and detection, cutting development timelines from months to weeks while reducing cost and logistical complexity
About US
We strive to create a safer, healthier world by transforming how society detects disease, protects the public, and uncovers truth. Through innovation, equality, and sustainability at our core, we empower partners and emerging enterprises in MedTech, forensics, veterinary science, and counterfeit protection to shape breakthroughs that widen access to healthcare and unlock new research opportunities for global benefit.
The Problem
There are threats across multiple sectors that need solutions. Crime detection, disease and product validation are all areas that the public demands excellence in.
The issue is that existing approaches to testing are expensive, time consuming and require specialist training to achieve.
For example modern forensic labs report that traditional toxicology screens often fail to identify compounds of interest, requiring advanced high‑resolution mass spectrometry and liquid chromatography–tandem mass spectrometry. Additional issues related to novel diseases of interest to humans (either directly or indirectly) means new approaches are needed.
OUR SOLUTION
Synthetic antibodies
known as aptamers
Produced using arobust, repaeatable methodology
DNA/RNA-based molecules
engineered for high specificity
Tailored to end-user
requirements
Our Technology
Aptamers provide a platform technology which can be intergrated into existing rapid detection and diagnostic processes.
10 to 50 times cheaper production costs compared to antibodies
Free from biological manufacturing constraints
Can reach markets where complex logistic simplicity is critical (chemically stable not requiring cold‑chain storage or transport)
Enable logistics cost savings of 30–200% and increased supply‑chain resilience
Critically, aptamers can support diagnosis/detection where is currently not possible, opening opportunities for new product development.
Rapid Development
Lower Costs
Faster Time-to-Market
Global Deployability
Value Proposition
Aptamers are a powerful platform technology that can significantly accelerate product development. Unlike many conventional technologies that require 6–12 months for design and validation, aptamers can be developed and validated in as little as six weeks. This dramatically shortens time-to-market, reduces R&D costs, and enables rapid responses to emerging threats.
In addition, aptamers support global deployment. Because they
are chemically stable and do not require cold-chain storage or
transport, they can reduce logistics costs by 30–200% while
improving supply-chain resilience. Beyond speed and scalability, aptamers also unlock new possibilities for innovative research and product development that are not accessible with current approaches.
Our team
Dr Thomas Arron Illingworth
Project lead and Co-Founder
Dr Rebecca Mallender
Principle Technical advisor and
Co founder
Dr Ana Flavia Belchior de Andrade Priniciple Scientific advisor and
Co founder
Contact us
Get in touch with the our team to find out more.